nach oben

Erschienen in:

05.03.2024 | REVIEW

Lipid metabolism and its implications in tumor cell plasticity and drug resistance: what we learned thus far?

verfasst von: Ravichandran Vishwa, Bandari BharathwajChetty, Sosmitha Girisa, Babu Santha Aswani, Mohammed S. Alqahtani, Mohamed Abbas, Mangala Hegde, Ajaikumar B. Kunnumakkara

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Metabolic reprogramming, a hallmark of cancer, allows cancer cells to adapt to their specific energy needs. The Warburg effect benefits cancer cells in both hypoxic and normoxic conditions and is a well-studied reprogramming of metabolism in cancer. Interestingly, the alteration of other metabolic pathways, especially lipid metabolism has also grabbed the attention of scientists worldwide. Lipids, primarily consisting of fatty acids, phospholipids and cholesterol, play essential roles as structural component of cell membrane, signalling molecule and energy reserves. This reprogramming primarily involves aberrations in the uptake, synthesis and breakdown of lipids, thereby contributing to the survival, proliferation, invasion, migration and metastasis of cancer cells. The development of resistance to the existing treatment modalities poses a major challenge in the field of cancer therapy. Also, the plasticity of tumor cells was reported to be a contributing factor for the development of resistance. A number of studies implicated that dysregulated lipid metabolism contributes to tumor cell plasticity and associated drug resistance. Therefore, it is important to understand the intricate reprogramming of lipid metabolism in cancer cells. In this review, we mainly focused on the implication of disturbed lipid metabolic events on inducing tumor cell plasticity-mediated drug resistance. In addition, we also discussed the concept of lipid peroxidation and its crucial role in phenotypic switching and resistance to ferroptosis in cancer cells. Elucidating the relationship between lipid metabolism, tumor cell plasticity and emergence of resistance will open new opportunities to develop innovative strategies and combinatorial approaches for the treatment of cancer.

Graphical Abstract

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021). Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660CrossRefPubMed

Graham, T. A., & Sottoriva, A. (2017). Measuring cancer evolution from the genome. The Journal of Pathology, 241(2), 183–191. https://doi.org/10.1002/path.4821CrossRefPubMed

Cagan, R., & Meyer, P. (2017). Rethinking cancer: Current challenges and opportunities in cancer research. Disease Models & Mechanisms, 10(4), 349–352. https://doi.org/10.1242/dmm.030007CrossRef

Barrios, C. H., Werutsky, G., & Martinez-Mesa, J. (2015). The global conduct of cancer clinical trials: challenges and opportunities. American Society of Clinical Oncology Education Book, e132–139. https://doi.org/10.14694/EdBook_AM.2015.35.e132

Hanahan, D. (2022). Hallmarks of cancer: New dimensions. Cancer Discovery, 12(1), 31–46. https://doi.org/10.1158/2159-8290.CD-21-1059CrossRefPubMed

You, M., Xie, Z., Zhang, N., Zhang, Y., Xiao, D., Liu, S., et al. (2023). Signaling pathways in cancer metabolism: Mechanisms and therapeutic targets. Signal Transduction and Targeted Therapy, 8(1), 196. https://doi.org/10.1038/s41392-023-01442-3CrossRefPubMedPubMedCentral

Juliano, R. L. (2020). Addressing cancer signal transduction pathways with antisense and siRNA oligonucleotides. NAR Cancer, 2(3), zcaa025. https://doi.org/10.1093/narcan/zcaa025CrossRefPubMedPubMedCentral

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013CrossRefPubMed

Frohling, S., & Dohner, H. (2008). Chromosomal abnormalities in cancer. New England Journal of Medicine, 359(7), 722–734. https://doi.org/10.1056/NEJMra0803109CrossRefPubMed

10.

Nong, S., Han, X., Xiang, Y., Qian, Y., Wei, Y., Zhang, T., et al. (2023). Metabolic reprogramming in cancer: Mechanisms and therapeutics. MedComm (2020), 4(2), e218. https://doi.org/10.1002/mco2.218CrossRefPubMed

11.

Koppenol, W. H., Bounds, P. L., & Dang, C. V. (2011). Otto Warburg’s contributions to current concepts of cancer metabolism. Nature Reviews Cancer, 11(5), 325–337. https://doi.org/10.1038/nrc3038CrossRefPubMed

12.

Rohrig, F., & Schulze, A. (2016). The multifaceted roles of fatty acid synthesis in cancer. Nature Reviews Cancer, 16(11), 732–749. https://doi.org/10.1038/nrc.2016.89CrossRefPubMed

13.

Martin-Perez, M., Urdiroz-Urricelqui, U., Bigas, C., & Benitah, S. A. (2022). The role of lipids in cancer progression and metastasis. Cell Metabolism, 34(11), 1675–1699. https://doi.org/10.1016/j.cmet.2022.09.023CrossRefPubMed

14.

Fu, Y., Zou, T., Shen, X., Nelson, P. J., Li, J., Wu, C., et al. (2021). Lipid metabolism in cancer progression and therapeutic strategies. MedComm (2020), 2(1), 27–59. https://doi.org/10.1002/mco2.27CrossRefPubMed

15.

Su, X., & Abumrad, N. A. (2009). Cellular fatty acid uptake: A pathway under construction. Trends in Endocrinology and Metabolism, 20(2), 72–77. https://doi.org/10.1016/j.tem.2008.11.001CrossRefPubMed

16.

Abumrad, N., Coburn, C., & Ibrahimi, A. (1999). Membrane proteins implicated in long-chain fatty acid uptake by mammalian cells: CD36 FATP and FABPm. Biochimica et Biophysica Acta, 1441(1), 4–13. https://doi.org/10.1016/s1388-1981(99)00137-7CrossRefPubMed

17.

Anderson, C. M., & Stahl, A. (2013). SLC27 fatty acid transport proteins. Molecular Aspects of Medicine, 34(2–3), 516–528. https://doi.org/10.1016/j.mam.2012.07.010CrossRefPubMedPubMedCentral

18.

Liu, W., Chakraborty, B., Safi, R., Kazmin, D., Chang, C. Y., & McDonnell, D. P. (2021). Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and metastasis in cancer. Nature Communications, 12(1), 5103. https://doi.org/10.1038/s41467-021-25354-4CrossRefPubMedPubMedCentral

19.

Ladanyi, A., Mukherjee, A., Kenny, H. A., Johnson, A., Mitra, A. K., Sundaresan, S., et al. (2018). Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene, 37(17), 2285–2301. https://doi.org/10.1038/s41388-017-0093-zCrossRefPubMedPubMedCentral

20.

Tousignant, K. D., Rockstroh, A., Taherian Fard, A., Lehman, M. L., Wang, C., McPherson, S. J., et al. (2019). Lipid uptake is an androgen-enhanced lipid supply pathway associated with prostate cancer disease progression and bone metastasis. Molecular Cancer Research, 17(5), 1166–1179. https://doi.org/10.1158/1541-7786.MCR-18-1147CrossRefPubMed

21.

Zaidi, N., Lupien, L., Kuemmerle, N. B., Kinlaw, W. B., Swinnen, J. V., & Smans, K. (2013). Lipogenesis and lipolysis: The pathways exploited by the cancer cells to acquire fatty acids. Progress in Lipid Research, 52(4), 585–589. https://doi.org/10.1016/j.plipres.2013.08.005CrossRefPubMedPubMedCentral

22.

Mashima, T., Seimiya, H., & Tsuruo, T. (2009). De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. British Journal of Cancer, 100(9), 1369–1372. https://doi.org/10.1038/sj.bjc.6605007CrossRefPubMedPubMedCentral

23.

Swinnen, J. V., Brusselmans, K., & Verhoeven, G. (2006). Increased lipogenesis in cancer cells: New players, novel targets. Current Opinion in Clinical Nutrition and Metabolic Care, 9(4), 358–365. https://doi.org/10.1097/01.mco.0000232894.28674.30CrossRefPubMed

24.

Kamphorst, J. J., Cross, J. R., Fan, J., de Stanchina, E., Mathew, R., White, E. P., et al. (2013). Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proceedings National Academy of Science U S A, 110(22), 8882–8887. https://doi.org/10.1073/pnas.1307237110CrossRef

25.

Young, R. M., Ackerman, D., Quinn, Z. L., Mancuso, A., Gruber, M., Liu, L., et al. (2013). Dysregulated mTORC1 renders cells critically dependent on desaturated lipids for survival under tumor-like stress. Genes & Development, 27(10), 1115–1131. https://doi.org/10.1101/gad.198630.112CrossRef

26.

Argiles, J. M., Busquets, S., Stemmler, B., & Lopez-Soriano, F. J. (2014). Cancer cachexia: Understanding the molecular basis. Nature Reviews Cancer, 14(11), 754–762. https://doi.org/10.1038/nrc3829CrossRefPubMed

27.

Hopperton, K. E., Duncan, R. E., Bazinet, R. P., & Archer, M. C. (2014). Fatty acid synthase plays a role in cancer metabolism beyond providing fatty acids for phospholipid synthesis or sustaining elevations in glycolytic activity. Experimental Cell Research, 320(2), 302–310. https://doi.org/10.1016/j.yexcr.2013.10.016CrossRefPubMed

28.

Auciello, F. R., Bulusu, V., Oon, C., Tait-Mulder, J., Berry, M., Bhattacharyya, S., et al. (2019). A stromal lysolipid-autotaxin signaling axis promotes pancreatic tumor progression. Cancer Discovery, 9(5), 617–627. https://doi.org/10.1158/2159-8290.CD-18-1212CrossRefPubMedPubMedCentral

29.

Snaebjornsson, M. T., Janaki-Raman, S., & Schulze, A. (2020). Greasing the wheels of the cancer machine: The role of lipid metabolism in cancer. Cell Metabolism, 31(1), 62–76. https://doi.org/10.1016/j.cmet.2019.11.010CrossRefPubMed

30.

Fendt, S. M., Frezza, C., & Erez, A. (2020). Targeting metabolic plasticity and flexibility dynamics for cancer therapy. Cancer Discovery, 10(12), 1797–1807. https://doi.org/10.1158/2159-8290.CD-20-0844CrossRefPubMedPubMedCentral

31.

Koundouros, N., & Poulogiannis, G. (2020). Reprogramming of fatty acid metabolism in cancer. British Journal of Cancer, 122(1), 4–22. https://doi.org/10.1038/s41416-019-0650-zCrossRefPubMed

32.

Broadfield, L. A., Pane, A. A., Talebi, A., Swinnen, J. V., & Fendt, S. M. (2021). Lipid metabolism in cancer: New perspectives and emerging mechanisms. Developmental Cell, 56(10), 1363–1393. https://doi.org/10.1016/j.devcel.2021.04.013CrossRefPubMed

33.

Buhrmann, C., Brockmueller, A., Harsha, C., Kunnumakkara, A. B., Kubatka, P., Aggarwal, B. B., et al. (2021). Evidence that tumor microenvironment initiates epithelial-to-mesenchymal transition and calebin A can suppress it in colorectal cancer cells. Frontiers in Pharmacology, 12, 699842. https://doi.org/10.3389/fphar.2021.699842CrossRefPubMedPubMedCentral

34.

Kunnumakkara, A. B., Bordoloi, D., Sailo, B. L., Roy, N. K., Thakur, K. K., Banik, K., et al. (2019). Cancer drug development: The missing links. Experimental Biology and Medicine (Maywood, N.J.), 244(8), 663–689. https://doi.org/10.1177/1535370219839163CrossRefPubMed

35.

Lv, L., Yang, S., Zhu, Y., Zhai, X., Li, S., Tao, X., et al. (2022). Relationship between metabolic reprogramming and drug resistance in breast cancer. Frontiers in Oncology, 12, 942064. https://doi.org/10.3389/fonc.2022.942064CrossRefPubMedPubMedCentral

36.

Chen, X., Chen, S., & Yu, D. (2020). Metabolic reprogramming of chemoresistant cancer cells and the potential significance of metabolic regulation in the reversal of cancer chemoresistance. Metabolites, 10(7),https://doi.org/10.3390/metabo10070289

37.

Goncalves, A. C., Richiardone, E., Jorge, J., Polonia, B., Xavier, C. P. R., Salaroglio, I. C., et al. (2021). Impact of cancer metabolism on therapy resistance - Clinical implications. Drug Resistance Updates, 59, 100797. https://doi.org/10.1016/j.drup.2021.100797CrossRefPubMed

38.

Meacham, C. E., & Morrison, S. J. (2013). Tumour heterogeneity and cancer cell plasticity. Nature, 501(7467), 328–337. https://doi.org/10.1038/nature12624CrossRefPubMedPubMedCentral

39.

Nussinov, R., Tsai, C. J., & Jang, H. (2021). Anticancer drug resistance: An update and perspective. Drug Resistance Updates, 59, 100796. https://doi.org/10.1016/j.drup.2021.100796CrossRefPubMedPubMedCentral

40.

Tzoneva, G., Perez-Garcia, A., Carpenter, Z., Khiabanian, H., Tosello, V., Allegretta, M., et al. (2013). Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nature Medicine, 19(3), 368–371. https://doi.org/10.1038/nm.3078CrossRefPubMedPubMedCentral

41.

Li, Y., Wang, Z., Ajani, J. A., & Song, S. (2021). Drug resistance and cancer stem cells. Cell Communication and Signaling: CCS, 19(1), 19. https://doi.org/10.1186/s12964-020-00627-5CrossRefPubMedPubMedCentral

42.

McNeer, N. A., Philip, J., Geiger, H., Ries, R. E., Lavallee, V. P., Walsh, M., et al. (2019). Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. Leukemia, 33(8), 1934–1943. https://doi.org/10.1038/s41375-019-0402-3CrossRefPubMedPubMedCentral

43.

Boumahdi, S., & de Sauvage, F. J. (2020). The great escape: Tumour cell plasticity in resistance to targeted therapy. Nature Reviews Drug Discovery, 19(1), 39–56. https://doi.org/10.1038/s41573-019-0044-1CrossRefPubMed

44.

Toyokawa, G., Bersani, F., Bironzo, P., Picca, F., Tabbo, F., Haratake, N., et al. (2023). Tumor plasticity and therapeutic resistance in oncogene-addicted non-small cell lung cancer: From preclinical observations to clinical implications. Critical Reviews in Oncology Hematology, 184, 103966. https://doi.org/10.1016/j.critrevonc.2023.103966CrossRefPubMed

45.

Castro-Perez, E., Singh, M., Sadangi, S., Mela-Sanchez, C., & Setaluri, V. (2023). Connecting the dots: Melanoma cell of origin, tumor cell plasticity, trans-differentiation, and drug resistance. Pigment Cell & Melanoma Research, 36(5), 330–347. https://doi.org/10.1111/pcmr.13092CrossRef

46.

Li, W., Li, L., & Hui, L. (2020). Cell Plasticity in Liver Regeneration. Trends in Cell Biology, 30(4), 329–338. https://doi.org/10.1016/j.tcb.2020.01.007CrossRefPubMed

47.

Blanpain, C., & Fuchs, E. (2014). Stem cell plasticity. Plasticity of epithelial stem cells in tissue regeneration. Science, 344(6189), 1242281. https://doi.org/10.1126/science.1242281CrossRefPubMedPubMedCentral

48.

Yang, J., Antin, P., Berx, G., Blanpain, C., Brabletz, T., Bronner, M., et al. (2020). Guidelines and definitions for research on epithelial-mesenchymal transition. Nature Reviews Molecular Cell Biology, 21(6), 341–352. https://doi.org/10.1038/s41580-020-0237-9CrossRefPubMedPubMedCentral

49.

Nieto, M. A., Huang, R. Y., Jackson, R. A., & Thiery, J. P. (2016). Emt: 2016. Cell, 166(1), 21–45. https://doi.org/10.1016/j.cell.2016.06.028CrossRefPubMed

50.

Buhrmann, C., Yazdi, M., Popper, B., Kunnumakkara, A. B., Aggarwal, B. B., & Shakibaei, M. (2019). Induction of the epithelial-to-mesenchymal transition of human colorectal cancer by human TNF-beta (lymphotoxin) and its reversal by resveratrol. Nutrients, 11(3), https://doi.org/10.3390/nu11030704

51.

Kumar, V. E., Nambiar, R., De Souza, C., Nguyen, A., Chien, J., & Lam, K. S. (2022). Targeting epigenetic modifiers of tumor plasticity and cancer stem cell behavior. Cells, 11(9), https://doi.org/10.3390/cells11091403

52.

Luiken, J. J., Bonen, A., & Glatz, J. F. (2002). Cellular fatty acid uptake is acutely regulated by membrane-associated fatty acid-binding proteins. Prostaglandins Leukotrienes and Essential Fatty Acids, 67(2–3), 73–78. https://doi.org/10.1054/plef.2002.0401CrossRefPubMed

53.

Grabner, G. F., Xie, H., Schweiger, M., & Zechner, R. (2021). Lipolysis: Cellular mechanisms for lipid mobilization from fat stores. Nature Metabolism, 3(11), 1445–1465. https://doi.org/10.1038/s42255-021-00493-6CrossRefPubMed

54.

de Carvalho, C., & Caramujo, M. J. (2018). The Various Roles of Fatty Acids. Molecules, 23(10), https://doi.org/10.3390/molecules23102583

55.

Currie, E., Schulze, A., Zechner, R., Walther, T. C., & Farese, R. V., Jr. (2013). Cellular fatty acid metabolism and cancer. Cell Metabolism, 18(2), 153–161. https://doi.org/10.1016/j.cmet.2013.05.017CrossRefPubMedPubMedCentral

56.

Mallick, R., Basak, S., & Duttaroy, A. K. (2021). Fatty acids and evolving roles of their proteins in neurological, cardiovascular disorders and cancers. Progress in Lipid Research, 83, 101116. https://doi.org/10.1016/j.plipres.2021.101116CrossRefPubMed

57.

Zaoui, M., Morel, M., Louadj, L., Ferrand, N., Lamaziere, A., Uzan, C., et al. (2023). Adipocytes secretome from normal and tumor breast favor breast cancer invasion by metabolic reprogramming. Clinical and Translational Oncology, 25(5), 1389–1401. https://doi.org/10.1007/s12094-022-03035-yCrossRefPubMed

58.

Seo, J., Kim, K. S., Park, J. W., Cho, J. Y., Chang, H., Fukuda, J., et al. (2021). Metastasis-on-a-chip reveals adipocyte-derived lipids trigger cancer cell migration via HIF-1alpha activation in cancer cells. Biomaterials, 269, 120622. https://doi.org/10.1016/j.biomaterials.2020.120622CrossRefPubMed

59.

Feng, W. W., Wilkins, O., Bang, S., Ung, M., Li, J., An, J., et al. (2019). CD36-mediated metabolic rewiring of breast cancer cells promotes resistance to HER2-targeted therapies. Cell Reports, 29(11), 3405–3420. https://doi.org/10.1016/j.celrep.2019.11.008.

60.

Masetti, M., Carriero, R., Portale, F., Marelli, G., Morina, N., Pandini, M., et al. (2022). Lipid-loaded tumor-associated macrophages sustain tumor growth and invasiveness in prostate cancer. Journal of Experimental Medicine, 219(2),https://doi.org/10.1084/jem.20210564

61.

Large, V., Peroni, O., Letexier, D., Ray, H., & Beylot, M. (2004). Metabolism of lipids in human white adipocyte. Diabetes & Metabolism, 30(4), 294–309. https://doi.org/10.1016/s1262-3636(07)70121-0CrossRef

62.

Alves-Bezerra, M., & Cohen, D. E. (2017). Triglyceride metabolism in the liver. Comprehensive Physiology, 8(1), 1–8. https://doi.org/10.1002/cphy.c170012CrossRefPubMedPubMedCentral

63.

Ershov, P., Kaluzhskiy, L., Mezentsev, Y., Yablokov, E., Gnedenko, O., & Ivanov, A. (2021). Enzymes in the cholesterol synthesis pathway: Interactomics in the cancer context. Biomedicines, 9(8), https://doi.org/10.3390/biomedicines9080895

64.

Yamashita, A., Hayashi, Y., Matsumoto, N., Nemoto-Sasaki, Y., Oka, S., Tanikawa, T., et al. (2014). Glycerophosphate/Acylglycerophosphate acyltransferases. Biology (Basel), 3(4), 801–830. https://doi.org/10.3390/biology3040801CrossRefPubMed

65.

Pinkham, K., Park, D. J., Hashemiaghdam, A., Kirov, A. B., Adam, I., Rosiak, K., et al. (2019). Stearoyl CoA desaturase is essential for regulation of endoplasmic reticulum homeostasis and tumor growth in glioblastoma cancer stem cells. Stem Cell Reports, 12(4), 712–727. https://doi.org/10.1016/j.stemcr.2019.02.012CrossRefPubMedPubMedCentral

66.

Engel, N., Adamus, A., Frank, M., Kraft, K., Kuhn, J., Muller, P., et al. (2018). First evidence of SGPL1 expression in the cell membrane silencing the extracellular S1P siren in mammary epithelial cells. PLoS ONE, 13(5), e0196854. https://doi.org/10.1371/journal.pone.0196854CrossRefPubMedPubMedCentral

67.

Zhang, P., He, Q., Wang, Y., Zhou, G., Chen, Y., Tang, L., et al. (2022). Protein C receptor maintains cancer stem cell properties via activating lipid synthesis in nasopharyngeal carcinoma. Signal Transduction and Targeted Therapy, 7(1), 46. https://doi.org/10.1038/s41392-021-00866-zCrossRefPubMedPubMedCentral

68.

Howell, M. C., Green, R., Khalil, R., Foran, E., Quarni, W., Nair, R., et al. (2020). Lung cancer cells survive epidermal growth factor receptor tyrosine kinase inhibitor exposure through upregulation of cholesterol synthesis. FASEB Bioadvance, 2(2), 90–105. https://doi.org/10.1096/fba.2019-00081CrossRef

69.

Drexler, K., Schmidt, K. M., Jordan, K., Federlin, M., Milenkovic, V. M., Liebisch, G., et al. (2021). Cancer-associated cells release citrate to support tumour metastatic progression. Life Science Alliance, 4(6), https://doi.org/10.26508/lsa.202000903

70.

Harma, V., Knuuttila, M., Virtanen, J., Mirtti, T., Kohonen, P., Kovanen, P., et al. (2012). Lysophosphatidic acid and sphingosine-1-phosphate promote morphogenesis and block invasion of prostate cancer cells in three-dimensional organotypic models. Oncogene, 31(16), 2075–2089. https://doi.org/10.1038/onc.2011.396CrossRefPubMed

71.

Pisanu, M. E., Maugeri-Sacca, M., Fattore, L., Bruschini, S., De Vitis, C., Tabbi, E., et al. (2018). Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma. Journal of Experimental & Clinical Cancer Research, 37(1), 318. https://doi.org/10.1186/s13046-018-0989-7CrossRef

72.

Zhao, Y., Liu, X., Si, F., Huang, L., Gao, A., Lin, W., et al. (2022). Citrate promotes excessive lipid biosynthesis and senescence in tumor cells for tumor therapy. Advancement of Science (Weinh), 9(1), e2101553. https://doi.org/10.1002/advs.202101553CrossRef

73.

Mycielska, M. E., Dettmer, K., Rummele, P., Schmidt, K., Prehn, C., Milenkovic, V. M., et al. (2018). Extracellular citrate affects critical elements of cancer cell metabolism and supports cancer development in vivo. Cancer Research, 78(10), 2513–2523. https://doi.org/10.1158/0008-5472.CAN-17-2959CrossRefPubMed

74.

Mycielska, M. E., Patel, A., Rizaner, N., Mazurek, M. P., Keun, H., Patel, A., et al. (2009). Citrate transport and metabolism in mammalian cells: Prostate epithelial cells and prostate cancer. BioEssays, 31(1), 10–20. https://doi.org/10.1002/bies.080137CrossRefPubMed

75.

Iacobazzi, V., & Infantino, V. (2014). Citrate–new functions for an old metabolite. Biological Chemistry, 395(4), 387–399. https://doi.org/10.1515/hsz-2013-0271CrossRefPubMed

76.

Xie, Z., Liu, H., & Geng, M. (2017). Targeting sphingosine-1-phosphate signaling for cancer therapy. Science China Life Sciences, 60(6), 585–600. https://doi.org/10.1007/s11427-017-9046-6CrossRefPubMed

77.

Mendelson, K., Evans, T., & Hla, T. (2014). Sphingosine 1-phosphate signalling. Development, 141(1), 5–9. https://doi.org/10.1242/dev.094805CrossRefPubMedPubMedCentral

78.

Mukherjee, A., Wu, J., Barbour, S., & Fang, X. (2012). Lysophosphatidic acid activates lipogenic pathways and de novo lipid synthesis in ovarian cancer cells. Journal of Biological Chemistry, 287(30), 24990–25000. https://doi.org/10.1074/jbc.M112.340083CrossRefPubMedPubMedCentral

79.

Yung, Y. C., Stoddard, N. C., & Chun, J. (2014). LPA receptor signaling: Pharmacology, physiology, and pathophysiology. Journal of Lipid Research, 55(7), 1192–1214. https://doi.org/10.1194/jlr.R046458CrossRefPubMedPubMedCentral

80.

Jiang, S., Wang, X., Song, D., Liu, X., Gu, Y., Xu, Z., et al. (2019). Cholesterol induces epithelial-to-mesenchymal transition of prostate cancer cells by suppressing degradation of EGFR through APMAP. Cancer Research, 79(12), 3063–3075. https://doi.org/10.1158/0008-5472.CAN-18-3295CrossRefPubMed

81.

Shao, W. Q., Zhu, W. W., Luo, M. J., Fan, M. H., Li, Q., Wang, S. H., et al. (2022). Cholesterol suppresses GOLM1-dependent selective autophagy of RTKs in hepatocellular carcinoma. Cell Reports, 39(3), 110712. https://doi.org/10.1016/j.celrep.2022.110712CrossRefPubMed

82.

Shao, W., Zhu, W., Lin, J., Luo, M., Lin, Z., Lu, L., et al. (2020). Liver X receptor agonism sensitizes a subset of hepatocellular carcinoma to sorafenib by dual-inhibiting MET and EGFR. Neoplasia, 22(1), 1–9. https://doi.org/10.1016/j.neo.2019.08.002CrossRefPubMed

83.

Bian, X., Liu, R., Meng, Y., Xing, D., Xu, D., & Lu, Z. (2021). Lipid metabolism and cancer. Journal of Experimental Medicine, 218(1), https://doi.org/10.1084/jem.20201606

84.

Ma, Y., Temkin, S. M., Hawkridge, A. M., Guo, C., Wang, W., Wang, X. Y., et al. (2018). Fatty acid oxidation: An emerging facet of metabolic transformation in cancer. Cancer Letters, 435, 92–100. https://doi.org/10.1016/j.canlet.2018.08.006CrossRefPubMedPubMedCentral

85.

Blucher, C., Iberl, S., Schwagarus, N., Muller, S., Liebisch, G., Horing, M., et al. (2020). Secreted factors from adipose tissue reprogram tumor lipid metabolism and induce motility by modulating PPARalpha/ANGPTL4 and FAK. Molecular Cancer Research, 18(12), 1849–1862. https://doi.org/10.1158/1541-7786.MCR-19-1223CrossRefPubMed

86.

Valentino, A., Calarco, A., Di Salle, A., Finicelli, M., Crispi, S., Calogero, R. A., et al. (2017). Deregulation of MicroRNAs mediated control of carnitine cycle in prostate cancer: Molecular basis and pathophysiological consequences. Oncogene, 36(43), 6030–6040. https://doi.org/10.1038/onc.2017.216CrossRefPubMed

87.

Loo, S. Y., Toh, L. P., Xie, W. H., Pathak, E., Tan, W., Ma, S., et al. (2021). Fatty acid oxidation is a druggable gateway regulating cellular plasticity for driving metastasis in breast cancer. Science Advances, 7(41), eabh2443. https://doi.org/10.1126/sciadv.abh2443CrossRefPubMedPubMedCentral

88.

Li, P., Lu, M., Shi, J., Gong, Z., Hua, L., Li, Q., et al. (2020). Lung mesenchymal cells elicit lipid storage in neutrophils that fuel breast cancer lung metastasis. Nature Immunology, 21(11), 1444–1455. https://doi.org/10.1038/s41590-020-0783-5CrossRefPubMedPubMedCentral

89.

Ayala, A., Munoz, M. F., & Arguelles, S. (2014). Lipid peroxidation: Production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxidative Medicine and Cellular Longevity, 2014, 360438. https://doi.org/10.1155/2014/360438CrossRefPubMedPubMedCentral

90.

Stockwell, B. R. (2022). Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell, 185(14), 2401–2421. https://doi.org/10.1016/j.cell.2022.06.003CrossRefPubMedPubMedCentral

91.

Chen, X., Kang, R., Kroemer, G., & Tang, D. (2021). Broadening horizons: The role of ferroptosis in cancer. Nature Reviews Clinical Oncology, 18(5), 280–296. https://doi.org/10.1038/s41571-020-00462-0CrossRefPubMed

92.

Dixon, S. J., & Stockwell, B. R. (2014). The role of iron and reactive oxygen species in cell death. Nature Chemical Biology, 10(1), 9–17. https://doi.org/10.1038/nchembio.1416CrossRefPubMed

93.

Ursini, F., & Maiorino, M. (2020). Lipid peroxidation and ferroptosis: The role of GSH and GPx4. Free Radical Biology & Medicine, 152, 175–185. https://doi.org/10.1016/j.freeradbiomed.2020.02.027CrossRef

94.

Hangauer, M. J., Viswanathan, V. S., Ryan, M. J., Bole, D., Eaton, J. K., Matov, A., et al. (2017). Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature, 551(7679), 247–250. https://doi.org/10.1038/nature24297CrossRefPubMedPubMedCentral

95.

Viswanathan, V. S., Ryan, M. J., Dhruv, H. D., Gill, S., Eichhoff, O. M., Seashore-Ludlow, B., et al. (2017). Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature, 547(7664), 453–457. https://doi.org/10.1038/nature23007CrossRefPubMedPubMedCentral

96.

Khwairakpam, A. D., Shyamananda, M. S., Sailo, B. L., Rathnakaram, S. R., Padmavathi, G., Kotoky, J., et al. (2015). ATP citrate lyase (ACLY): A promising target for cancer prevention and treatment. Current Drug Targets, 16(2), 156–163. https://doi.org/10.2174/1389450115666141224125117CrossRefPubMed

97.

Lee, J., Shin, D., & Roh, J. L. (2023). Lipid metabolism alterations and ferroptosis in cancer: Paving the way for solving cancer resistance. European Journal of Pharmacology, 941, 175497. https://doi.org/10.1016/j.ejphar.2023.175497CrossRefPubMed

98.

Hegde, M., Kumar, A., Girisa, S., Alqahtani, M. S., Abbas, M., Goel, A., et al. (2023). Exosomal noncoding RNA-mediated spatiotemporal regulation of lipid metabolism: Implications in immune evasion and chronic inflammation. Cytokine & Growth Factor Reviews. https://doi.org/10.1016/j.cytogfr.2023.06.001CrossRef

99.

Tan, S. K., Hougen, H. Y., Merchan, J. R., Gonzalgo, M. L., & Welford, S. M. (2023). Fatty acid metabolism reprogramming in ccRCC: Mechanisms and potential targets. Nature Reviews. Urology, 20(1), 48–60. https://doi.org/10.1038/s41585-022-00654-6CrossRefPubMed

100.

Saliakoura, M., & Konstantinidou, G. (2023). Lipid metabolic alterations in KRAS mutant tumors: Unmasking new vulnerabilities for cancer therapy. International Journal of Molecular Sciences, 24(2), https://doi.org/10.3390/ijms24021793

101.

Guo, C., Zhang, L., Zhao, M., Ai, Y., Liao, W., Wan, L., et al. (2023). Targeting lipid metabolism with natural products: A novel strategy for gastrointestinal cancer therapy. Phytotherapy Research, 37(5), 2036–2050. https://doi.org/10.1002/ptr.7735CrossRefPubMed

102.

Qiao, X., Hu, Z., Xiong, F., Yang, Y., Peng, C., Wang, D., et al. (2023). Lipid metabolism reprogramming in tumor-associated macrophages and implications for therapy. Lipids in Health and Disease, 22(1), 45. https://doi.org/10.1186/s12944-023-01807-1CrossRefPubMedPubMedCentral

103.

Lim, S. A., Su, W., Chapman, N. M., & Chi, H. (2022). Lipid metabolism in T cell signaling and function. Nature Chemical Biology, 18(5), 470–481. https://doi.org/10.1038/s41589-022-01017-3CrossRefPubMed

104.

Chen, M., Shi, Z., Sun, Y., Ning, H., Gu, X., & Zhang, L. (2023). Prospects for anti-tumor mechanism and potential clinical application based on glutathione peroxidase 4 mediated ferroptosis. International Journal Molecular Sciences, 24(2), https://doi.org/10.3390/ijms24021607

105.

Liu, H., Forouhar, F., Seibt, T., Saneto, R., Wigby, K., Friedman, J., et al. (2022). Characterization of a patient-derived variant of GPX4 for precision therapy. Nature Chemical Biology, 18(1), 91–100. https://doi.org/10.1038/s41589-021-00915-2CrossRefPubMed

106.

Liu, S., Yan, S., Zhu, J., Lu, R., Kang, C., Tang, K., et al. (2022). Combination RSL3 treatment sensitizes ferroptosis- and EGFR-inhibition-resistant HNSCCs to cetuximab. International Journal of Molecular Sciences, 23(16), https://doi.org/10.3390/ijms23169014

107.

Wang, H., Wang, C., Li, B., Zheng, C., Liu, G., Liu, Z., et al. (2023). Discovery of ML210-Based glutathione peroxidase 4 (GPX4) degrader inducing ferroptosis of human cancer cells. European Journal of Medicinal Chemistry, 254, 115343. https://doi.org/10.1016/j.ejmech.2023.115343CrossRefPubMed

108.

Yang, J., Mo, J., Dai, J., Ye, C., Cen, W., Zheng, X., et al. (2021). Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer. Cell Death & Disease, 12(11), 1079. https://doi.org/10.1038/s41419-021-04367-3CrossRef

Titel: Lipid metabolism and its implications in tumor cell plasticity and drug resistance: what we learned thus far?
verfasst von: Ravichandran Vishwa
Bandari BharathwajChetty
Sosmitha Girisa
Babu Santha Aswani
Mohammed S. Alqahtani
Mohamed Abbas
Mangala Hegde
Ajaikumar B. Kunnumakkara
Publikationsdatum: 05.03.2024
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 1/2024
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-024-10170-1

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Lipid metabolism and its implications in tumor cell plasticity and drug resistance: what we learned thus far?

Abstract

Graphical Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Graphical Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation

Harnessing function of EMT in cancer drug resistance: a metastasis regulator determines chemotherapy response

Modulation of hypoxia-inducible factor-1 signaling pathways in cancer angiogenesis, invasion, and metastasis by natural compounds: a comprehensive and critical review

Cell plasticity modulation by flavonoids in resistant breast carcinoma targeting the nuclear factor kappa B signaling

Dynamic interplay of nuclear receptors in tumor cell plasticity and drug resistance: Shifting gears in malignant transformations and applications in cancer therapeutics

Sam68 is a druggable vulnerability point in cancer stem cells

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie